The role of topotecan in the treatment of small cell lung cancer

Research output: Contribution to journalReview article

Abstract

Topotecan is a chemotherapeutic agent that is active in the treatment of small cell lung cancer (SCLC). As a first-line agent in chemotherapy-naive patients with extensive disease SCLC, topotecan has a 39% response rate. As a second-line drug in SCLC patients with 'sensitive' disease and 'refractory' disease, the response rate is greater than 38% and less than 10%, respectively. The combination of topotecan and paclitaxel exhibits a promising overall response rate of 92% in chemotherapy-naive patients with extensive disease SCLC. Further studies are warranted with topotecan used in combination with other agents, including radiation therapy in patients with SCLC.

Original languageEnglish (US)
Pages (from-to)11-14
Number of pages4
JournalOncologist
Volume3
Issue number1
StatePublished - Mar 21 1998

Keywords

  • Extensive disease
  • Limited disease
  • Refractory disease
  • Sensitive disease
  • Small cell lung cancer
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The role of topotecan in the treatment of small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this